newsfilter
← Latest News
PR Newswire·

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes m